The future of antibiotics

Area of Science:

• Microbiology and Infectious Diseases
• Pharmaceutical Sciences
• Health Economics

Background:

• Antibiotic resistance is a growing global threat.
• The current market model for antibiotic research and development (R&D) is failing.
• Existing scientific, economic, and regulatory frameworks hinder the creation of novel antibiotics.

Purpose of the Study:

• To identify scientific, economic, and regulatory barriers contributing to the antibiotic market failure.
• To propose disruptive approaches for rekindling antibiotic R&D.
• To outline strategies for protecting new antibiotics from misuse.

Main Methods:

• Review of scientific, economic, and regulatory challenges in antibiotic R&D.
• Exploration of novel scientific strategies, including disarming pathogens and modulating host responses.
• Analysis of economic incentives like public-private partnerships and value-based pricing.
• Assessment of regulatory reforms for traditional and limited-use antibiotic pathways.

Main Results:

• Scientific innovation can focus on novel screening and alternative treatment paradigms (e.g., disarming pathogens).
• Economic strategies should prioritize push incentives and high unmet need development.
• Regulatory reform is essential for viable development pathways and international harmonization.
• Protecting new antibiotics from overuse is critical post-marketing.

Conclusions:

• Overcoming the antibiotic market failure requires a multi-faceted approach.
• Disruptive scientific, economic, and regulatory strategies are necessary to ensure a future pipeline of effective antibiotics.
• Combating antibiotic resistance necessitates challenging long-standing dogma in drug development and stewardship.